PFE announces buyout at 1/2 companies projected short term future value and ARNA management / BOD takes the deal.
What is it that scares ARNA management /BOD about the current trials? Whatever it is a completely knowledgeable group of scientist from PFE seem to know otherwise. Obviously there is an issue. The question is ...... is there another group of scientist who have looked behind the blind and are willing to make their company billions.
Reversibly reduce lymphocyte levels at sites of inflammation, while maintaining components of immune function. At week 12, the etrasimod 2 mg group met the primary and all secondary endpoints.
Crohn’s disease, inflammatory bowel diseases, ulcerative colitis.